ResMed (RMD) Fundamental Analysis: Revenue, Earnings & Valuation

9.36 / 10

Outperform

Fundamental analysis rates Outperform with a 9.4/10 score. ROE 25.86% and ROA 18.62% sit in the top quartile, as do profit margin 27.22% and cash‑flow‑to‑revenue 34.04%. Cash‑MV is slightly negative, and Profit‑MV shows modest risk, but overall strength remains high.

Analysis Checks(9/10)

ROA (%)

Value18.62

Score3/3

Weight19.79%

1M Return1.62%

Annualized return on equity (%)

Value25.86

Score3/3

Weight17.68%

1M Return1.46%

Net cash flow from operating activities / Operating revenue (%)

Value34.04

Score3/3

Weight26.35%

1M Return2.06%

Profit-MV

Value0.13

Score1/3

Weight-54.53%

1M Return-6.43%

Net profit margin (%)

Value27.22

Score3/3

Weight18.33%

1M Return1.51%

Cash-UP

Value-0.12

Score2/3

Weight-44.72%

1M Return-4.91%

Annualized net profit margin on total assets (%)

Value18.62

Score3/3

Weight19.79%

1M Return1.62%

ROE (diluted) (%)

Value23.47

Score3/3

Weight17.17%

1M Return1.41%

ROE (%)

Value25.86

Score3/3

Weight17.68%

1M Return1.46%

Cash-MV

Value-0.22

Score3/3

Weight62.45%

1M Return4.44%

Is RMD fundamentally strong?

RMD scores 9.36/10 on fundamentals and holds a Discounted valuation at present. Backed by its 12.06% ROE, 27.53% net margin, 22.24 P/E ratio, 5.23 P/B ratio, and 19.53% earnings growth, these metrics solidify its Outperform investment rating.